Recombinant human WDR62 protein; Source: E. coli derived, PGEX-4T; Tag: GST; Domain: 281-630 aa of BC017261
Conjugate
Unconjugated
Applications
Application Notes
IP: 0.5-4.0 μg for 1.0-3.0 mg of total protein lysate IHC: 1:50-1:500 IF/ICC: 1:200-1:800
General Notes
This product (Catalog No. DPABH-27339) is a rabbit-derived polyclonal antibody raised against human WDR62, targeting the amino acid region 281–630 of the protein. This antibody exhibits cross-reactivity with Human WDR62 from mouse. It has been affinity purified by Protein A. The WD40-repeat protein 62 (WDR62) is a scaffold protein that recruits different components of the JNK signaling pathway to regulate several human diseases including neurological disorders, infertility, and tumorigenesis (PMID: 33937237). Moreover, WDR62 participates in diverse biological processes, especially mitotic spindle organization via regulating centriole biogenesis and the function of centriole-associated protein (PMID: 35093571). DPABH-27339 is suitable for use in IP (0.5-4.0 μg for 1.0-3.0 mg of total protein lysate), IHC (1:50–1:500), IF/ICC (1:200–1:800) applications. DPABH-27339 is supplied as a liquid formulation in PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. For long-term storage, keep at −20 °C. For short-term use, store at 2–8 °C. Avoid repeated freeze–thaw cycles to maintain antibody integrity and performance.
Target
Alternative Names
C19orf14; WD repeat domain 62; WD repeat-containing protein 62
My Review for Rabbit Anti-Human WDR62 (a.a. 281-630) Polyclonal antibody
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.